These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 7777531)

  • 1. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1.
    Li CJ; Wang C; Friedman DJ; Pardee AB
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5461-4. PubMed ID: 7777531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription.
    Harrod R; Nacsa J; Van Lint C; Hansen J; Karpova T; McNally J; Franchini G
    J Biol Chem; 2003 Apr; 278(14):12310-8. PubMed ID: 12501250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tat gene and protein of the human immunodeficiency virus type 1.
    Caputo A; Grossi MP; Rossi C; Campioni D; Balboni PG; Corallini A; Barbanti-Brodano G
    New Microbiol; 1995 Jan; 18(1):87-110. PubMed ID: 7760763
    [No Abstract]   [Full Text] [Related]  

  • 4. Canventol inhibits HIV-1 replication by Tat-induced Tar-independent mechanism.
    Biswas DK; Tius MA; Zhuo J; Pardee AB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):120-7. PubMed ID: 8680882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infection and replication of Tat- human immunodeficiency viruses: genetic analyses of LTR and tat mutations in primary and long-term human lymphoid cells.
    Chang LJ; Zhang C
    Virology; 1995 Aug; 211(1):157-69. PubMed ID: 7645208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA transcripts of the human immunodeficiency virus transactivation response element can inhibit action of the viral transactivator.
    Graham GJ; Maio JJ
    Proc Natl Acad Sci U S A; 1990 Aug; 87(15):5817-21. PubMed ID: 1696012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.
    Drysdale CM; Pavlakis GN
    J Virol; 1991 Jun; 65(6):3044-51. PubMed ID: 2033665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human immunodeficiency virus long terminal repeat includes a specialised initiator element which is required for Tat-responsive transcription.
    Rittner K; Churcher MJ; Gait MJ; Karn J
    J Mol Biol; 1995 May; 248(3):562-80. PubMed ID: 7752225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reciprocal in vitro interactions between human herpesvirus-6 and HIV-1 Tat.
    Di Luca D; Secchiero P; Bovenzi P; Rotola A; Caputo A; Monini P; Cassai E
    AIDS; 1991 Sep; 5(9):1095-8. PubMed ID: 1657039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein.
    Kamine J; Subramanian T; Chinnadurai G
    Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8510-4. PubMed ID: 1924310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain.
    Ariumi Y; Kaida A; Hatanaka M; Shimotohno K
    Biochem Biophys Res Commun; 2001 Sep; 287(2):556-61. PubMed ID: 11554765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular approaches to inhibit HIV-1 tat expression and functions.
    Grossi MP; Caputo A; Zucchini S; Bozzini R; Marconi PC; Manservigi R; Barbanti-Brodano G; Balboni PG
    Year Immunol; 1993; 7():199-204. PubMed ID: 8396820
    [No Abstract]   [Full Text] [Related]  

  • 13. Repression in vitro, by human adenovirus E1A protein domains, of basal or Tat-activated transcription of the human immunodeficiency virus type 1 long terminal repeat.
    Song CZ; Loewenstein PM; Green M
    J Virol; 1995 May; 69(5):2907-11. PubMed ID: 7707515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV Tat, its TARgets and the control of viral gene expression.
    Brigati C; Giacca M; Noonan DM; Albini A
    FEMS Microbiol Lett; 2003 Mar; 220(1):57-65. PubMed ID: 12644228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1.
    Dis Markers; 1990; 8(2):107. PubMed ID: 2201474
    [No Abstract]   [Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation.
    Kolson DL; Collman R; Hrin R; Balliet JW; Laughlin M; McGann KA; Debouck C; Gonzalez-Scarano F
    J Gen Virol; 1994 Aug; 75 ( Pt 8)():1927-34. PubMed ID: 8046394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator.
    Marcello A; Zoppé M; Giacca M
    IUBMB Life; 2001 Mar; 51(3):175-81. PubMed ID: 11547919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of a diphtheria toxin A gene by expression of human immunodeficiency virus-1 Tat and Rev proteins in transfected cells.
    Harrison GS; Maxwell F; Long CJ; Rosen CA; Glode LM; Maxwell IH
    Hum Gene Ther; 1991; 2(1):53-60. PubMed ID: 1863640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus type 2 (HIV-2) trans-activator (Tat): functional domains and the search for trans-dominant negative mutants.
    Arya SK
    AIDS Res Hum Retroviruses; 1993 Sep; 9(9):839-48. PubMed ID: 8257633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation.
    Verhoef K; Bauer M; Meyerhans A; Berkhout B
    AIDS Res Hum Retroviruses; 1998 Nov; 14(17):1553-9. PubMed ID: 9840288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.